6 Analysts Have This To Say About MetLife
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on MetLife (NYSE:MET) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $95.67, a high estimate of $101.00, and a low estimate of $90.00. Observing a 2.43% increase, the current average has risen from the previous average price target of $93.40.
Decoding Analyst Ratings: A Detailed Look
The analysis of recent analyst actions sheds light on the perception of MetLife by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Meredith | UBS | Raises | Buy | $98.00 | $94.00 |
| Elyse Greenspan | Wells Fargo | Raises | Overweight | $97.00 | $94.00 |
| Brian Meredith | UBS | Lowers | Buy | $94.00 | $95.00 |
| Elyse Greenspan | Wells Fargo | Raises | Overweight | $94.00 | $92.00 |
| Yaron Kinar | Mizuho | Announces | Outperform | $101.00 | - |
| Ryan Krueger | Keefe, Bruyette & Woods | Lowers | Outperform | $90.00 | $92.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MetLife. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MetLife compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of MetLife's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on MetLife analyst ratings.
Discovering MetLife: A Closer Look
MetLife is one of the largest life insurers in the US by assets and provides a variety of life insurance and annuity products. It is organized into six segments: Group Benefits, Retirement and Income Solutions, Asia, Latin America, Europe/Middle East/Africa (EMEA), and MetLife Holdings (products in run-off). Group Benefits and RIS are US-based, contributing to around 48% of the firm's 2024 adjusted earnings. The Asia segment contributes around 25% of earnings, mainly tied to Japan. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of 2024 earnings. The EMEA and MetLife Holdings segments contributed around 4% and 10% of 2024 earnings, respectively.
MetLife's Financial Performance
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3M period, MetLife faced challenges, resulting in a decline of approximately -7.74% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MetLife's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.85%, the company may face hurdles in effective cost management.
Return on Equity (ROE): MetLife's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.89%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): MetLife's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.11%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: MetLife's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.69, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
The Core of Analyst Ratings: What Every Investor Should Know
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.